These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Lugthart S; Figueroa ME; Bindels E; Skrabanek L; Valk PJ; Li Y; Meyer S; Erpelinck-Verschueren C; Greally J; Löwenberg B; Melnick A; Delwel R Blood; 2011 Jan; 117(1):234-41. PubMed ID: 20855866 [TBL] [Abstract][Full Text] [Related]
7. The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA. Senyuk V; Premanand K; Xu P; Qian Z; Nucifora G PLoS One; 2011; 6(6):e20793. PubMed ID: 21695170 [TBL] [Abstract][Full Text] [Related]
9. Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis. Kataoka K; Kurokawa M Cancer Sci; 2012 Aug; 103(8):1371-7. PubMed ID: 22494115 [TBL] [Abstract][Full Text] [Related]
10. EVI1 drives leukemogenesis through aberrant ERG activation. Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844 [TBL] [Abstract][Full Text] [Related]
11. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573 [TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178 [TBL] [Abstract][Full Text] [Related]
13. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383 [TBL] [Abstract][Full Text] [Related]
14. [The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms]. Tanaka A Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237 [TBL] [Abstract][Full Text] [Related]
15. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia. Yamakawa N; Kaneda K; Saito Y; Ichihara E; Morishita K PLoS One; 2012; 7(1):e30706. PubMed ID: 22295105 [TBL] [Abstract][Full Text] [Related]
16. Evi1 upregulates Fbp1 and supports progression of acute myeloid leukemia through pentose phosphate pathway activation. Mizuno H; Koya J; Masamoto Y; Kagoya Y; Kurokawa M Cancer Sci; 2021 Oct; 112(10):4112-4126. PubMed ID: 34363719 [TBL] [Abstract][Full Text] [Related]
18. Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Laricchia-Robbio L; Nucifora G Blood Cells Mol Dis; 2008; 40(2):141-7. PubMed ID: 17913523 [TBL] [Abstract][Full Text] [Related]
19. Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9. Li F; He W; Geng R; Xie X Clin Transl Oncol; 2020 Jan; 22(1):137-143. PubMed ID: 31054042 [TBL] [Abstract][Full Text] [Related]